SMMT — Summit Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1599298 ·
Last close
$13.02
Market Cap
$10.39B
52W High
$19.42
52W Low
$12.25
ADV30
4,438,073
Next earnings
2026-10-19
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -220,496,000 | -215,700,000 | 752,185,000 | 419,365,000 | 122,202,000 |
| Mar 2026 | 0 | — | -195,212,000 | -189,424,000 | 647,856,000 | 106,515,000 | 101,924,000 |
| Dec 2025 | 0 | — | -224,875,000 | -219,172,000 | 751,182,000 | 225,266,000 | 92,322,000 |
| Sep 2025 | 0 | — | -234,211,000 | -231,793,000 | 261,729,000 | 238,554,000 | 69,466,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-458,433,000
Investing CF
$-262,570,000
Financing CF
$842,509,000
CapEx
$-1,389,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.12
As of
2026-07-26
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,699,283,000
Inventory
—
Receivables
$557,000
ST Investments
$271,313,000
EBIT TTM
$-866,623,000
Pretax Income TTM
$-856,039,000
Interest Exp TTM
$0
Analysts
13
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -1,094,374,000 | -1,079,586,000 | 751,182,000 | 92,322,000 | — | -322,930,000 |
| Dec 2024 | 0 | -210,977,000 | -221,315,000 | 435,560,000 | 46,812,000 | — | -142,106,000 |
| Dec 2023 | 0 | -88,735,000 | -614,928,000 | 202,949,000 | 125,257,000 | — | -76,760,000 |
| Dec 2022 | 705,000 | -63,621,000 | -78,782,000 | 664,168,000 | 537,514,000 | — | -41,582,000 |
TTM Snapshot
Revenues TTM
$1,529,000
NetIncome TTM
$-118,506,000
OpCashFlow TTM
$0
Assets (Latest)
$435,560,000
Forward EPS
$-1.19
Max Pain — expiry 2026-08-21
max pain strike: $14.00 · spot: $13.02 · call oi: 7,592 · put oi: 5,468
Expected Move to 2026-08-21:
±$1.67
(12.86%) —
implied range
$11.35 –
$14.70
· ATM straddle on $13.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CYTK | CYTOKINETICS INC | $10.47B | $77.13 | — |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | $10.77B | $467.32 | — |
| ABVX | Abivax S.A. | $10.89B | $124.92 | — |
| RDY | DR REDDYS LABORATORIES LTD | $9.87B | $11.85 | — |
| AXSM | Axsome Therapeutics, Inc. | $11.22B | $217.99 | — |
News headlines (Yahoo Finance, 1h cache)
Summit Therapeutics Says Extended Follow-Up Reveals Stronger Survival Advantages with lead Cancer Drug
2026-07-24 11:01 · Yahoo
Summit Therapeutics Inc (SMMT) Q2 2026 Earnings Call Highlights: Strong Cash Position and ...
2026-07-24 05:01 · Yahoo
Summit Therapeutics (SMMT) Updates Phase III Survival Data, Is The Stock Still A Bargain?
2026-07-24 02:11 · Yahoo
Summit Therapeutics Q2 Earnings Call Highlights
2026-07-23 22:06 · Yahoo
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026
2026-07-23 20:05 · Yahoo
Summit Therapeutics (SMMT) Stock Looks Stretched On Fresh Lung Cancer Data
2026-07-23 09:14 · Yahoo
Did New HARMONi Survival Data Just Shift Summit Therapeutics' (SMMT) Ivonescimab Investment Narrative?
2026-07-23 07:12 · Yahoo
Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
2026-07-22 20:30 · Yahoo
SMMT Stock Gains After Summit Reports Strong Lung Cancer Survival Results — Investors Await Q2 Earnings
2026-07-22 18:57 · Yahoo
Summit Therapeutics shares advance after updated Phase III cancer trial results (NASDAQ:SMMT)
2026-07-22 12:24 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.